Acute Limb Ischemia

Acute limb ischemia (ALI) is a sudden decrease in limb perfusion that threatens tissue viability, requiring immediate diagnosis and revascularization to prevent limb loss ^[5]D5.

Also Called / Synonyms

• Acute lower limb ischemia (ALI) ^[5]D5
• Acute leg ischemia
• Acute peripheral arterial occlusion

Classification Axes

ALI is classified along three axes that guide management : severity, etiology, and anatomic level. The Rutherford classification is the standard for severity stratification, categorizing ischemia into grades I through III based on clinical findings ^[5]D5. The table below summarizes the Rutherford grades, their key features, and the implied urgency.

Grades IIA and IIB are the most common presentations at referral, with 53.8% and 36.3% of patients, respectively, in a contemporary series ^[2]B3b. The presence of motor deficit (class IIB) is the critical threshold that mandates emergent revascularization, as delay beyond 48 hours from symptom onset is associated with a 66.7% 30-day reintervention rate compared with 23.5% when anticoagulation is started within 6 hours ^[2]B3b.

Etiology further divides ALI into embolic (sudden onset, often from a cardiac source) and thrombotic (in situ thrombosis on pre-existing atherosclerotic or graft disease). The distinction is crucial because it informs the choice of surgical versus endovascular therapy, but the evidence base for this classification relies on clinical history and imaging rather than trial data. Anatomic level (aortoiliac, femoropopliteal, tibial) is determined by angiography and influences revascularization strategy.

Clinical Significance

ALI is a limb- and potentially life-threatening condition that remains a leading cause of major amputation and cardiovascular death ^[5]D5. In the VOYAGER PAD trial, acute limb ischemia was a component of the primary composite efficacy endpoint, underscoring its importance as a clinical event in patients with peripheral artery disease ^[1]A1b[7]D5. The combination of low-dose rivaroxaban (2.5 mg twice daily) plus aspirin reduced the incidence of acute limb ischemia along with other vascular outcomes, though the absolute risk remains substantial ^[1]A1b[1]A1b.

These classification axes, severity, etiology, and anatomy, form the foundation for operative decision-making, as discussed in the subsequent section on pathophysiology and the surgical lesion.

Pearl: ALI is a limb- and life-threatening emergency; even with optimal therapy, the risk of amputation and cardiovascular events remains high.

From the classification framework outlined above, the mechanistic basis of acute limb ischemia (ALI) follows two distinct pathways that converge on a common final cascade of tissue injury. The surgeon must understand these pathways because the nature of the occluding material, embolus versus thrombus, dictates the revascularization strategy and the urgency of intervention.

Two Paths to Occlusion

Embolic occlusion accounts for 64% of native-artery ALI ^[14]C4. The embolus is typically a fragment of a cardiac mural thrombus ( atrial fibrillation , myocardial infarction, valvular disease) or, less commonly, a piece of atheromatous debris from a proximal aneurysm or a paradoxical embolus through a patent foramen ovale. Emboli lodge at arterial bifurcations, the common femoral, popliteal, and brachial bifurcations, where the vessel caliber abruptly narrows. Because the embolus lands in a previously normal artery, collaterals are absent, and the ischemic insult is sudden and severe. The classic presentation is the 6 Ps: pain, pallor, pulselessness, paresthesia, paralysis, and poikilothermia. The time to irreversible tissue loss is short: muscle necrosis begins after 4 to 6 hours of complete ischemia ^[14]C4.

In situ thrombosis occurs in an artery already diseased by atherosclerosis, a stent, a graft, or a popliteal aneurysm. The event is often a plaque rupture or a low-flow state that triggers thrombosis. In popliteal artery aneurysms, the percent thrombus within the aneurysm sac is the key predictor of acute limb-threatening events: a higher percent thrombus confers a relative risk ratio of 17.9 for an acutely limb-threatening presentation (P < 0.01) ^[12]B3b. The patient with thrombotic ALI may have some pre-existing collateral circulation, so the clinical onset can be less abrupt, but the run-off is often compromised by chronic disease, making limb salvage more dependent on the number of patent tibial arteries (pTA) ^[13]B3b.

The Ischemic Cascade

Once the arterial lumen is occluded, the downstream tissue enters a predictable sequence of injury:

1. Cessation of oxygen delivery → switch from aerobic to anaerobic metabolism.
2. Anaerobic glycolysis → accumulation of lactate and hydrogen ions → intracellular acidosis.
3. ATP depletion → failure of the Na+/K+ ATPase pump → cellular swelling (cytotoxic edema).
4. Membrane permeability increases → release of intracellular contents (myoglobin, potassium, reactive oxygen species).
5. Endothelial injury → loss of vascular integrity → interstitial edema → elevated compartment pressure.
6. Compartment syndrome → further capillary collapse → worsening ischemia → a self-amplifying cycle.
7. Irreversible necrosis → muscle and nerve death → rhabdomyolysis , renal failure, and limb loss if revascularization is not performed.

Revascularization itself introduces ischemia-reperfusion injury (IRI). The sudden reintroduction of oxygenated blood generates a burst of reactive oxygen species from mitochondria, triggering an inflammatory response that can worsen capillary leak, cause no-reflow phenomena, and precipitate acute kidney injury. In a randomized trial of remote ischemic preconditioning (RIPC) in ALI, RIPC reduced mitochondrial oxidative stress at 24 hours but did not improve clinical outcomes (renal function, compartment syndrome, or amputation) ^[23]A1b. This finding underscores the difficulty of pharmacologically interrupting the cascade once it is underway.

The Surgical Lesion

The surgical lesion is the obstructing material, a soft, friable embolus or a firmer, organized thrombus, and the damaged arterial wall beneath it. In embolic cases, the artery proximal to the occlusion is usually normal, and simple embolectomy with a Fogarty catheter restores flow. In thrombotic cases, the underlying atherosclerotic plaque, aneurysm, or graft neointima must be addressed (bypass, endarterectomy, or angioplasty/stenting) to prevent reocclusion. The number of patent tibial arteries (pTA) at presentation is the strongest independent predictor of limb salvage: 5-year limb salvage drops from 100% with 3 pTA to 0% with 0 pTA (P = 0.001) ^[13]B3b. This quantifies the runoff, the "runway" for the revascularization to succeed.

Etiologic Variants

• Aortic dissection: ALI in type B dissection is a malperfusion syndrome. The dissection flap extends into the iliac arteries, compressing the true lumen. Endovascular fenestration or stenting of the true lumen is the primary therapy, with limb salvage rates of 93% at 18 months ^[25]B3b. ALI in this setting predicts a 3.5-fold increase in mortality (P = 0.02) ^[25]B3b.
• Iatrogenic: Arterial cannulation for mechanical circulatory support (e.g., VA-ECMO) causes ALI in 69% of patients with femoral cannulation ^[24]B3b. The mechanism is a combination of occlusion by the cannula, thrombosis, and distal embolization. Percutaneous closure devices (e.g., MANTA) reduce the risk but still carry a 5.0% incidence of ALI ^[22]C4.
• Pediatric: ALI in children is overwhelmingly iatrogenic (89.9% from arterial cannulation) and is managed conservatively in 87% of cases, with an amputation rate of only 2.4% ^[16]C4.

Flowchart of the Pathogenetic Cascade

Pearl: The number of patent tibial arteries (pTA) on preoperative angiography or duplex is the single most important prognostic marker for limb salvage, knowing it should guide the aggressiveness of the revascularization strategy ^[13]B3b.

The pathophysiologic cascade of embolic occlusion or in-situ thrombosis translates into a disease burden that is both age-dependent and increasingly driven by systemic atherosclerosis. The overall incidence of acute limb ischemia (ALI) is 1-2 per 100,000 person-years in general populations, though contemporary series report a mean age of 78 years (range 65-80) with a slight male predominance (49% male in one 220-patient cohort) ^[14]C4. In pediatric populations, ALI is far rarer, with a mean age of 2.14 years and 66.3% male; 89.9% of cases are iatrogenic, most commonly from femoral artery cannulation ^[16]C4.

Temporal Trends

Over the past two decades, patients presenting with ALI have become older and carry a higher burden of cardiovascular comorbidities, while limb salvage rates remain excellent (95% at 30 days) ^[14]C4. The COVID-19 pandemic was associated with a relative increase in ALI incidence due to virus-associated thrombotic complications; in one Indonesian cohort, 65.4% of ALI patients presented during the pandemic period (RR 2.46 for revascularization success, likely reflecting increased use of fluoroscopic guidance) ^[28]B3b.

Etiology

ALI arises from two principal mechanisms: embolism (64.1% of native artery occlusions) and acute arterial thrombosis (35.9%) ^[14]C4. Embolic sources include cardiac ( atrial fibrillation , left ventricular thrombus, prosthetic valve) and proximal arterial aneurysms (popliteal artery aneurysm, PAA). Thrombotic ALI typically occurs in the setting of pre-existing peripheral artery disease (PAD), graft occlusion, or hypercoagulable states. Popliteal artery aneurysms carry a particularly high risk: percent thrombus on duplex ultrasound, not diameter, predicts acutely limb-threatening events (RRR 17.9; 95%) ^[12]B3b. In patients with type B aortic dissection, ALI complicates approximately 6% of cases and is associated with 3.5-fold increased mortality (OR 3.5; 95% CI 1.1-10) ^[25]B3b.

Risk Factors

Table 1 summarizes the key risk factors for ALI occurrence and adverse outcomes, drawn from multivariable analyses.

Special Populations

• Pediatric ALI is predominantly iatrogenic (arterial cannulation) and managed conservatively in 87% of cases, with an amputation rate of 2.4% and negligible mortality directly attributable to ALI ^[16]C4.
• Post-procedural ALI complicates peripheral VA-ECMO in 69% of patients, a risk essentially eliminated by using the Propella (percutaneous biventricular support) strategy ^[24]B3b. ALI also occurs after transcatheter aortic valve implantation (TAVI), particularly in patients with high ischemic risk (concomitant CAD, diabetes, PVD) ^[27]D5. Infected aortic bypass grafts carry a 29.4% incidence of ALI during management ^[18]C4.
• COVID-19-associated ALI shares similar risk factors (dyslipidemia, heart disease) but responds well to revascularization when fluoroscopic guidance is used ^[28]B3b.

Seasonal Variation

No seasonal variation has been reported in the available literature.

Pearl: In any patient with ALI, count the number of patent tibial arteries on preoperative imaging, this simple metric predicts both limb salvage and survival (5-year limb salvage 0% with zero patent tibial vessels vs 100% with three) ^[13]B3b.

The urgency of revascularization in acute limb ischemia (ALI) is determined by the severity of presenting signs and symptoms, which reflect the depth and duration of tissue ischemia. The focused examination is the first triage filter, guiding immediate classification into Rutherford categories and directing the choice between revascularization and primary amputation.

Presenting Symptoms

The hallmark of ALI is the abrupt onset of pain, often severe and out of proportion to the visible skin changes. The classic "six Ps", pain, pallor, pulselessness, poikilothermia, paresthesia, and paralysis, capture the progression from reversible to irreversible ischemia. Pain arises from nerve and muscle ischemia; pallor and poikilothermia (cold limb) reflect loss of arterial inflow. Pulselessness is detected by palpation and Doppler interrogation. Sensory loss (paresthesia) and motor weakness (paralysis) indicate advanced nerve ischemia and are the critical predictors of limb viability. The timeline is variable but critical: the presence of motor deficit signifies immediately threatened or irreversible ischemia and mandates revascularization within hours.

Focused Examination

• Inspection: Assess skin color (pallor, mottling, cyanosis), capillary refill, and muscle contour. A pale, cool limb with delayed capillary refill suggests severe ischemia. Mottling extending above the ankle indicates advanced ischemia.
• Palpation: Palpate femoral, popliteal, dorsalis pedis, and posterior tibial pulses. An absent Doppler signal at the ankle confirms critical ischemia. Compare with the contralateral limb.
• Neurological exam: Test light touch, pinprick sensation, and motor function (toe flexion/extension, ankle dorsiflexion/plantarflexion). Loss of motor function (paralysis) defines Rutherford IIb or III ischemia.
• Rutherford classification (adapted from ^[13]B3b):
• I (Viable): No sensory loss, no motor deficit, audible Doppler arterial signal.
• IIa (Marginally threatened): Minimal sensory loss, no motor deficit, audible Doppler signal.
• IIb (Immediately threatened): Significant sensory loss, mild-to-moderate motor deficit, inaudible arterial Doppler.
• III (Irreversible): Profound sensory loss, paralysis, muscle rigidity, absent Doppler signals.

Phenotypic Variants

The distinction between embolic and thrombotic ALI guides management . The table below summarizes key differentiating features.

Popliteal artery aneurysm (PAA) is a specific thrombotic variant: percent thrombus, not diameter, predicts symptomatic and acutely limb-threatening events ^[12]B3b. PAA thrombosis or distal embolization can present with ALI and loss of tibio-pedal runoff ^[13]B3b.

Red Flags

• Paralysis (loss of motor function) for >6 hours: indicates irreversible muscle necrosis and risks compartment syndrome.
• Muscle rigidity and pain on passive stretch: signs of compartment syndrome and irreversible ischemia.
• Absent arterial Doppler signals at both popliteal and pedal levels: suggests Rutherford III.
• Tense compartments and loss of skin turgor: mandate consideration of primary amputation rather than revascularization.

Atypical Presentations

• COVID-19 -associated ALI: Described in a case series of 7 severe (Rutherford III) patients, where fever was the most common COVID-19 symptom and lower-limb ulceration was the predominant ischemic manifestation. Laboratory findings showed neutrophilia, lymphopenia, elevated D-dimer, and fibrinogen ^[32]C4.
• Pediatric ALI: Most often iatrogenic from arterial cannulation (89.9% of cases), with the common femoral artery most frequently affected. Presentation may be subtle, and conservative treatment is first-line in 87% of cases ^[16]C4.

The focused examination, combined with the clinical history, directly guides the immediate use of imaging such as duplex ultrasound or CTA, as discussed in the next section.

Pearl: Embolic ALI has sudden onset with normal contralateral pulses and a cardiac source; thrombotic ALI is acute-on-chronic with prior claudication and often due to atherosclerotic plaque or popliteal aneurysm.

The clinical suspicion of acute limb ischemia, once raised by history and the classic 6 Ps, is a bedside diagnosis that demands immediate confirmation and characterisation to guide revascularization. The evaluation must be rapid, systematic, and tailored to the urgency of the presentation.

Clinical Diagnosis and Bedside Assessment

The diagnosis of acute limb ischemia is primarily clinical. The presence of sudden-onset rest pain, pallor, pulselessness, poikilothermia, paresthesia, or paralysis in a limb is sufficient to establish the diagnosis. The handheld Doppler is the essential bedside tool: an absent arterial Doppler signal with a preserved venous signal confirms severe ischemia and warrants immediate intervention ^[29]A1c. Motor loss (Rutherford class IIB or III) signifies irreversible ischemia and mandates revascularization without delay, bypassing further imaging that would postpone treatment.

Imaging: Gold Standard and Modalities

Duplex ultrasound (DUS) is the first-line imaging modality for acute limb ischemia. It is fast, portable, repeatable, and provides both anatomic and hemodynamic data by identifying the level of occlusion and distinguishing embolic from thrombotic patterns ^[35]D5. In pediatric acute limb ischemia, ultrasound is the most commonly used diagnostic means ^[16]C4. CT angiography (CTA) offers superior spatial resolution for proximal lesions (aortoiliac occlusions) and is valuable for planning endovascular intervention, but it delays revascularization and should be reserved for hemodynamically stable patients without motor deficit. Invasive angiography remains the gold standard during intervention, but it is not a diagnostic tool to be performed before revascularization when motor deficit is present.

Laboratory Studies

Laboratory findings are nonspecific but supportive. Elevated D-dimer, fibrinogen, and C-reactive protein reflect the underlying thrombotic state ^[32]C4. Elevated lactate and creatine kinase indicate tissue ischemia. Neutrophilia and lymphopenia may accompany the acute inflammatory response ^[32]C4. However, no laboratory test alone can confirm or exclude the diagnosis.

Diagnostic Algorithm

The following algorithm integrates clinical assessment and imaging to guide the decision for revascularization.

Step 1: Any patient with suspected acute limb ischemia undergoes immediate bedside Doppler assessment. Step 2: If motor or sensory loss is present (Rutherford class IIB or III), proceed directly to revascularization, simultaneous imaging (DUS) can be performed at the bedside without delaying the intervention. Step 3: If no motor deficit exists, obtain urgent DUS (or CTA if DUS is inconclusive for proximal lesions) to confirm the occlusion, identify the level, and guide the choice between catheter-directed thrombolysis, surgical embolectomy, or percutaneous mechanical thrombectomy. Step 4: If imaging does not confirm an arterial occlusion, consider alternative diagnoses.

Differential Diagnosis

Several conditions mimic acute limb ischemia and must be distinguished rapidly:

• Phlegmasia cerulea dolens (massive iliofemoral deep vein thrombosis), presents with a cyanotic, swollen, painful limb but with palpable pulses on Doppler.
• Acute arterial dissection, may cause sudden pain and pulse deficit but often with a history of hypertension or connective tissue disease.
• Compartment syndrome, pain out of proportion, tense swelling, and pain with passive stretch; pulses are initially present.
• Critical limb-threatening ischemia (chronic), progressive symptoms over weeks to months, not acute.
• Neurologic deficit (e.g., stroke, spinal cord lesion), absent pain or pallor, normal pulses.

Pearl: The most time-sensitive diagnostic tool is the clinical exam; do not delay revascularization for imaging when motor deficit is present. The presence of an absent arterial Doppler signal with a venous signal is the decision point for immediate intervention.

After confirming the diagnosis of acute limb ischemia (ALI) through focused history, physical examination, and Doppler interrogation, the clinician must immediately grade the severity of ischemia, this single step determines the window for intervention and the choice of revascularization strategy. The Rutherford classification (Table 1) remains the standard for this purpose, converting the clinical picture into a numeric trigger for operation ^[41]D5.

Rutherford Clinical Staging

The classification divides ALI into three categories based on the presence of sensory loss, motor deficit, and arterial/venous Doppler signals ^[41]D5.

The key distinction is between IIa and IIb: a patient with any motor deficit (IIb) has a threatened limb that will progress to irreversible necrosis within hours, mandating emergent surgical embolectomy or bypass rather than catheter-directed thrombolysis, which takes too long ^[41]D5[42]D5. Sensory loss confined to the toes (IIa) still allows time for thrombolysis if no contraindications exist.

Risk Stratification for Perioperative Mortality

Beyond the limb itself, patient factors independently predict mortality after ALI. The presence of critical limb ischemia (tissue loss) at presentation carries a hazard ratio of 8.1 for decreased survival, and renal failure (HR 2.5) and poor outflow (HR 2.0) further worsen prognosis ^[37]B3b. The NCDR PVI AKI risk model provides a validated integer scoring system for acute kidney injury after lower extremity intervention, which is directly relevant to ALI patients: scores ≤4 correspond to the lower 20% of risk, while scores ≥12 predict the upper 20% ^[48]B3b. AKI after intervention occurs in 7.4% of procedures and is associated with a 7.1% in-hospital mortality (vs 0.7% without AKI) ^[48]B3b.

For patients with ALI due to popliteal artery aneurysm, a cluster analysis of the POPART registry identified that the preoperative clinical presentation (acute ischemia vs non-emergency symptoms) is a stronger determinant of perioperative complications than the epidemiological profile alone ^[47]B2b. This reinforces that staging severity, not just comorbidities, drives risk.

Integrating Scoring into Decision-Making

The Rutherford category trumps all other factors in determining the immediate plan: a IIb limb goes to the operating room even if the patient has high surgical risk. However, after the revascularization decision is made, the NCDR AKI score and comorbid burden inform perioperative optimization, for example, using balanced crystalloids, minimizing contrast volume, and considering temporary hemofiltration in high-risk patients. The dual-layered approach (limb severity → intervention choice; patient risk → perioperative care) is the foundation of safe ALI management and directly feeds into the Acute Management and Resuscitation section.

Pearl: The single most important decision in acute limb ischemia is distinguishing a viable (I) from a threatened (IIa vs IIb) limb, any motor deficit (IIb) demands emergent surgery, not thrombolysis, because the window for limb salvage closes within hours ^[41]D5.

With severity classified and the limb deemed salvageable, acute management begins immediately, anticoagulation, resuscitation, and preparation for revascularization proceed in parallel. The goal is to halt thrombus propagation, optimize tissue perfusion, and correct metabolic derangements while the revascularization strategy is finalized.

Step 1: Immediate Systemic Anticoagulation

Administer unfractionated heparin (UFH) as a 80 U/kg IV bolus followed by 18 U/kg/hr continuous infusion, titrated to an aPTT of 60-80 seconds (1.5-2.5 times control). This prevents distal thrombus extension and preserves collateral flow. In patients with known or suspected heparin-induced thrombocytopenia (HIT), a condition associated with a 15.9% incidence of acute limb ischemia after cardiac surgery ^[57]B3b, UFH must be avoided. Use a direct thrombin inhibitor instead: argatroban 2 mcg/kg/min (adjusted for hepatic impairment) or bivalirudin 0.15 mg/kg/hr, both titrated to aPTT 1.5-3.0 times baseline. Low-molecular-weight heparin (e.g., enoxaparin 1 mg/kg SC every 12 hours) is an alternative when HIT is not a concern, though its longer half-life makes it less desirable in patients who may require urgent operative intervention.

Step 2: Resuscitation and Metabolic Optimization

Correct hypovolemia with balanced crystalloids to maintain mean arterial pressure ≥65 mm Hg. The lactate-to-albumin ratio (LAR) is independently associated with 28-day in-hospital death or amputation (AUC 0.762 in one cohort) and can guide resuscitation intensity ^[49]B3b. In COVID-19 -associated ALI, elevated D-dimer, fibrinogen, and inflammatory markers (hs-CRP, PCT) are common; antibiotics are indicated when open wounds are present ^[32]C4. Do not elevate the ischemic limb, keeping it at or below heart level maximizes gravitational perfusion pressure. Provide adequate analgesia (IV opioids as needed) to reduce catecholamine-driven vasoconstriction.

Step 3: Identify and Address the Underlying Etiology

While anticoagulation is underway, determine whether the occlusion is embolic or thrombotic. Embolic sources (e.g., atrial fibrillation , valvular vegetations) require echocardiography; if a cardiac source is identified, long-term anticoagulation with warfarin or a direct oral anticoagulant is indicated after revascularization. Thrombotic ALI in the setting of atherosclerosis or hypercoagulable states may benefit from antiplatelet therapy ( aspirin 325 mg loading, then 81 mg daily) in addition to heparin. In pediatric ALI, most often catheter-related, nonoperative management with anticoagulation alone is successful in 94% of cases, owing to robust collateral development ^[54]C4.

Step 4: Prepare for Revascularization Without Delay

Revascularization should not be postponed for extensive imaging in Rutherford IIb or III ischemia. The choice between surgical embolectomy, catheter-directed thrombolysis, or percutaneous mechanical thrombectomy is guided by severity, etiology, and institutional capability, this decision is detailed in the next section. While awaiting intervention, continue heparin infusion and monitor distal pulses, sensory-motor function, and compartment pressure hourly. If compartment syndrome develops (pain out of proportion, tense swelling, paresthesias), perform emergent fasciotomy before or immediately after revascularization.

Pearl: Immediate systemic anticoagulation with unfractionated heparin is the cornerstone of acute ALI management; in patients with heparin-induced thrombocytopenia, switch to a direct thrombin inhibitor without delay ^[57]B3b.

Once systemic anticoagulation is initiated and the patient is hemodynamically optimized, the central question becomes whether revascularization is indicated and, if so, with what urgency. The decision hinges on the severity of ischemia, the etiology (embolic vs thrombotic), the patient's comorbidities, and the viability of the limb. The goal is to restore perfusion before irreversible tissue loss occurs, while avoiding futile interventions in patients with non-salvageable extremities or prohibitive operative risk.

Indications for Revascularization

Every patient with acute limb ischemia (ALI) and a viable or marginally threatened limb (Rutherford class I, IIa, or IIb) warrants consideration for revascularization. The exception is the non-viable limb (Rutherford class III), where the muscle is already necrotic and revascularization would precipitate life-threatening reperfusion syndrome; primary major amputation is the appropriate intervention in this setting. In a contemporary series of 220 patients, 3.2% underwent direct major limb amputation without revascularization ^[14]C4. Among nonagenarians with ALI, 14.7% were treated palliatively, including 8 with irreversible ischemia and advanced dementia or malignancy, and none survived beyond 10 days ^[62]C4. These data underscore the importance of honest prognostic assessment before proceeding.

Revascularization is also indicated for patients with ALI secondary to popliteal artery aneurysm (PAA) thrombosis or distal embolization, where bypass surgery with or without preoperative thrombolysis achieves 5-year limb salvage of 83% ^[13]B3b. In type B aortic dissection presenting with ALI, endovascular therapy (aortic fenestration or aorto-iliac stenting) is the primary approach, with limb salvage of 93% at 18 months ^[25]B3b.

Timing and Urgency

The window for limb salvage is narrow. Experimental and clinical data traditionally suggest that irreversible neuromuscular changes begin after 6 hours of complete ischemia, but this is not absolute; the actual tolerable ischemia time depends on collateral circulation, the level of occlusion, and the metabolic demands of the ischemic tissue. The urgency of revascularization is stratified by the Rutherford classification: class I (viable) can be worked up semi-electively within 24 hours, class IIa (marginally threatened) requires revascularization within hours, and class IIb (immediately threatened) demands emergency intervention within minutes to hours. Treatment delay >1 day after vascular consultation was an independent risk factor for major amputation in one series (odds ratio not reported) ^[14]C4.

Operative vs Nonoperative Evidence

Two principal revascularization strategies exist: open surgery (embolectomy, thrombectomy, bypass) and endovascular therapy (catheter-directed thrombolysis [CDT], percutaneous mechanical thrombectomy [PMT], angioplasty/stenting). The choice depends on the etiology, the clot burden, the surgical risk, and the available expertise.

Open surgery remains the standard for embolic occlusions, especially in patients with contraindications to thrombolysis (recent surgery, active bleeding, stroke). In a large nationwide database analysis of 277,440 hospitalizations for ALI, open revascularization was associated with reduced odds of major amputation (adjusted odds ratio, 0.83; 95% CI, 0.78-0.89) but greater odds of in-hospital mortality (adjusted odds ratio, 1.25; 95% CI, 1.17-1.33) and nonhome discharge ^[63]B3b. Open surgery also carried higher risks of intraoperative, respiratory, and infectious complications ^[63]B3b. This trade-off, lower amputation risk but higher perioperative morbidity, favors open surgery in patients with robust physiologic reserve and a clear embolic source.

Endovascular therapy, primarily CDT or PMT, is preferred for thrombotic occlusions, especially in patients with Rutherford class I or IIa ischemia and a short symptom duration. A meta-analysis of 26 studies (214,683 patients) found no significant difference in early amputation rates between endovascular and open approaches (risk ratio, 0.93; 95% CI, 0.80-1.09) or in 30-day mortality, but endovascular therapy was associated with shorter hospital stay (mean difference, -2.43 days; 95% CI, -3.84 to -1.02) and lower infection rates, albeit with a higher risk of intracranial hemorrhage (risk ratio, 1.89; 95% CI, 1.13-3.15) ^[17]B2a. These data suggest that for patients with suitable anatomy, an endovascular-first strategy is reasonable, but conversion to open surgery should be low-threshold if thrombolysis fails or complications arise.

Pharmacomechanical thrombectomy (PMT) offers a single-session alternative to CDT. A randomized trial of 50 patients with thrombotic ALI without motor deficit compared PMT (Rotarex device) with CDT. PMT showed a tendency toward higher technical success (96% vs 80%, not statistically significant) and lower amputation rates (1 below-knee amputation vs 5 amputations in the CDT group), with no 30-day mortality in the PMT group versus 8% in the CDT group ^[21]A1b. A meta-analysis of 4 observational studies (607 patients) confirmed comparable 30-day limb loss and mortality between PMT and CDT, but PMT was associated with a higher risk of distal embolization (OR 2.09; 95% CI, 1.22-3.59) and acute kidney injury (OR 4.77; 95% CI, 1.85-12.30) ^[30]A1a. Hospital stay was shorter with PMT (mean difference, -1.27 days; 95% CI, -1.84 to -0.70) ^[30]A1a.

Thrombolysis alone (without mechanical adjunct) can achieve limb salvage rates up to 90% in acute embolic occlusions with short symptom duration, but bleeding complications occur in up to 47% of cases ^[61]B2a. The choice between CDT and surgery should be individualized, weighing the risk of bleeding against the benefits of a less invasive approach.

Controversies and Guideline Disagreement

Pearl: The decision to operate is not binary, a patient with a non-viable limb (Rutherford class III) should undergo primary amputation, not revascularization, to avoid fatal reperfusion syndrome; for all others, the choice between open and endovascular therapy should balance the risk of amputation (lower with open surgery) against the risk of perioperative mortality (lower with endovascular therapy), using the patient's physiologic reserve as the tiebreaker.

Once the decision to operate is made, the choice of revascularization technique, open, endovascular, or hybrid, depends on the etiology (embolic vs thrombotic), ischemia severity (Rutherford class), thrombus burden, and patient physiology. The evidence base has shifted from a default surgical approach to a nuanced strategy that balances limb salvage against perioperative risk.

Open Surgical Revascularization

Open surgery remains the standard for Rutherford class IIb ischemia and for embolic occlusions where a single-clamp embolectomy under local anesthesia can be definitive ^[62]C4. In a 2025 analysis of 277,440 ALI hospitalizations, open revascularization was associated with a reduced odds of major amputation at 90 days (adjusted odds ratio [aOR] 0.83; 95% CI 0.78-0.89) compared with endovascular therapy, but at the cost of higher in-hospital mortality (aOR 1.25), nonhome discharge (aOR 1.82), and greater odds of intraoperative (aOR 1.30), respiratory (aOR 1.57), and infectious complications (aOR 1.19) ^[63]B3b. The message: open surgery optimizes limb preservation in suitable candidates but carries measurable perioperative risk.

Common femoral endarterectomy (CFE), often performed as part of a hybrid procedure, remains a cornerstone for infrainguinal disease. In a multicenter series of 150 CFE procedures, the 6-month mortality was 6.7%, and 3-month local complications occurred in 7.3% ^[71]B3b. Risk factors for mortality included chronic kidney disease (OR 4.19), an American Society of Anesthesiologists score ≥4 (OR 7.75), and chronic limb-threatening ischemia (OR 4.47) ^[71]B3b. Body mass index >25 kg/m² was associated with local complications (OR 4.01) ^[71]B3b.

Endovascular Revascularization

Endovascular options include catheter-directed thrombolysis (CDT), pharmacomechanical thrombectomy (PMT), and aspiration/mechanical thrombectomy (MT). A 2025 meta-analysis of 4 retrospective studies (607 patients) comparing PMT with CDT found no significant differences in technical success (OR 0.69), 30-day limb loss (OR 1.22), or 30-day mortality (OR 1.17) ^[30]A1a. However, PMT was associated with higher rates of distal embolization (OR 2.09) and acute kidney injury (OR 4.77), though hospital stay was shorter by a mean of 1.27 days (95% CI -1.84 to -0.70) ^[30]A1a.

A separate meta-analysis of 10 studies (1083 patients) evaluating thromboaspiration (TA) and MT reported a pooled 30-day major amputation rate of 5% (95% CI 1-8%) and 30-day mortality of 3% (95% CI 1-5%) ^[31]A1a. Technical success alone was 57% (95% CI 39-75%), increasing to 97% (95% CI 94-100%) with adjunctive therapy (angioplasty, stenting, or CDT) ^[31]A1a.

The AngioJet PMT system requires careful attention to cycle number. In a prospective cohort of 92 patients, >150 cycles/second was associated with higher 30-day mortality (16.1% vs 9.3%; p=0.007) and a trend toward lower limb salvage (85% vs 95.7% at 1057 days; p=0.081) ^[68]B2b. Postoperative acute kidney injury (HR 2.97; p<0.001) and COVID-19 infection (HR 2.75; p=0.010) were also independent predictors of mortality ^[68]B2b.

Perioperative Optimization

Antithrombotic management is central to perioperative care. In the VOYAGER PAD trial, post-lower extremity revascularization patients receiving rivaroxaban 2.5 mg twice daily plus aspirin (81-100 mg daily) had a 15% reduction in first events and a 14% reduction in total primary endpoint events compared with aspirin alone (HR 0.86; 95%; p=0.02) ^[65]A1b. An estimated 4.4 primary events per 100 participants were avoided over 3 years ^[65]A1b. A subanalysis of the COMPASS trial (2632 patients undergoing surgery/procedure) found no significant difference in perioperative ischemic or bleeding events between patients receiving rivaroxaban 2.5 mg twice daily plus aspirin, rivaroxaban 5 mg twice daily, or aspirin alone, with bleeding rates of 3.1% to 4.2% ^[64]A1b.

Preoperative optimization should address modifiable risk factors: anemia (HR 1.81; p=0.014) and ALI severity (HR 1.73; p=0.032) predict lower survival in nonagenarians ^[62]C4. For patients requiring CFE, careful selection is warranted in those with CKD, high ASA class, or CLTI ^[71]B3b.

Special Populations

In nonagenarians (mean age, 78.4% women), 89.6% of those treated underwent revascularization, with 1-year limb salvage of 96% and 1-year survival of 48% ^[62]C4. Palliative care was appropriate for those with irreversible ischemia, advanced dementia, or concomitant cerebral/intestinal ischemia ^[62]C4. For radiation-induced arteriopathy, no evidence favors open over endovascular treatment, but close long-term follow-up is needed due to late recurrence ^[70]C4.

Pearl: Open surgery reduces amputation risk by 17% (aOR 0.83) but increases mortality by 25% (aOR 1.25) compared with endovascular therapy; patient selection based on functional status and ischemia severity is the critical determinant of choice ^[63]B3b.

Following revascularization, the clinical course is frequently complicated by reperfusion injury, compartment syndrome, bleeding, and thromboembolic events. The management of these complications, both disease-specific and procedure-specific, directly determines limb salvage and survival.

Hemorrhagic Complications

Bleeding is the most common complication of thrombolysis, reported in up to 47% of cases ^[61]B2a. Catheter-directed thrombolysis carries a higher risk of major bleeding than pharmacomechanical thrombectomy, though the difference was not statistically significant (P=0.67) ^[30]A1a. Intracranial hemorrhage occurs more frequently with endovascular therapy (RR 1.89) ^[17]B2a. Management follows a stepwise protocol:

1. Withhold thrombolytic agent and heparin .
2. Reverse anticoagulation (protamine for heparin, fresh frozen plasma or prothrombin complex concentrate for warfarin ).
3. Compression or surgical exploration for access-site bleeding.
4. Transfusion if hemoglobin < 7 g/dL or hemodynamic instability.

In the ILAILL trial, iloprost (intra‑arterial 3000 ng bolus + IV infusion 0.5-2.0 ng/kg/min for 6 h/day, 4-7 days) did not increase bleeding or hypotension versus placebo ^[9]A1b.

Reperfusion Injury and Compartment Syndrome

Ischemia‑reperfusion injury (IRI) can cause limb‑threatening compartment syndrome, myoglobinuria, and multi‑organ failure ^[76]D5. Fasciotomy rates are similar after endovascular vs open revascularization ^[17]B2a. Management relies on early recognition: measure compartment pressure when pain, pallor, paresthesia, or paralysis develop. Fasciotomy is indicated when compartment pressure exceeds 30 mmHg or diastolic pressure minus compartment pressure is < 30 mmHg. Supportive care includes aggressive hydration, urinary alkalinization, and monitoring creatine kinase and renal function ^[76]D5.

Infectious Complications

Open revascularization carries higher infection rates than endovascular therapy (RR 0.33 for endovascular) ^[17]B2a. Graft infection, often polymicrobial (48.6% of cases), is managed with antibiotic‑impregnated polymethylmethacrylate (ab‑PMMA) beads (tobramycin/ vancomycin most common), repeated debridement, and muscle‑flap closure. This strategy achieves wound sterilization in 94.1% and limb salvage in 86.5% at mean 26 months ^[26]C4. Reinfection after aortic bypass graft infection is 12.7% (95% CI 8.6%-) ^[18]C4; 30‑day mortality after graft infection reaches 27.8% ^[18]C4.

Thromboembolic and Occlusive Complications

Endovascular therapy is associated with higher periprocedural reintervention rates (RR 1.94) but comparable mid‑term reintervention ^[75]B2a. Distal embolization occurs more frequently with pharmacomechanical thrombectomy (OR 2.09) ^[30]A1a. In popliteal artery aneurysms, percent thrombus (not diameter) predicts acutely limb‑threatening events ^[12]B3b. Repeat revascularization, either catheter‑directed thrombolysis or surgical bypass, is the mainstay for graft occlusion. Acute kidney injury is also more common after PMT (OR 4.77) ^[30]A1a.

What NOT to Do

• Do not continue thrombolysis in the presence of major bleeding without reversal ^[61]B2a.
• Do not delay fasciotomy when compartment pressure exceeds 30 mmHg; delayed fasciotomy worsens myonecrosis and renal failure ^[76]D5.
• Do not use systemic anticoagulation alone as definitive treatment for ALI unless the patient is moribund, revascularization is required.

Controversies and Guideline Disagreement

Pearl: Proactive monitoring for compartment syndrome, bleeding, and graft occlusion, with early fasciotomy, reversal of anticoagulation, and repeat revascularization as needed, keeps limb salvage rates > 85% in most series ^{[26]C4[75]B2a}.

The complications of revascularization, reperfusion injury, compartment syndrome, and bleeding, underscore why the choice of initial therapy matters, a lesson learned through decades of clinical trials that have shaped the modern treatment algorithm.

The Shift from Surgery to Thrombolysis

Before the 1990s, surgical embolectomy and bypass were the default for acute limb ischemia (ALI). The STILE trial (1994) randomized 393 patients with nonembolic occlusion to surgery or catheter-directed thrombolysis ( urokinase or rt-PA ) and changed practice ^[77]A1b. For patients with ischemia of <14 days duration, thrombolysis produced lower amputation rates (p=0.052) and shorter hospital stays (p<0.04); at 6 months, amputation-free survival was significantly better (p=0.01). In chronic ischemia (>14 days), surgery was superior (p=0.001). An economic analysis found similar total costs between strategies ($22,171 vs $19,775; p=NS) ^[78]B2c. However, failure of catheter placement occurred in 28% of the thrombolysis arm, and fibrinogen depletion predicted hemorrhagic complications (p<0.01) ^[77]A1b.

Adjuvant Pharmacotherapy

The ILAILL study (2006) tested whether perioperative iloprost , a prostacyclin analog, could improve outcomes after surgical revascularization for ALI ^[9]A1b. In 300 patients, iloprost reduced mortality from 10.6% to 4.7% (relative risk 2.61; 95%; p=0.03; NNT ≈ 17). The combined incidence of death and amputation was 19.9% in the placebo group vs 14.1% in the iloprost group (p=0.12). Major cardiovascular events were also lower (33.1% vs 22.8%; p=0.03). Despite these benefits, iloprost was not widely adopted because the effect was modest and further confirmatory data were lacking.

The Modern Antithrombotic Era

VOYAGER PAD (2020) established the current standard of dual-pathway inhibition after lower-extremity revascularization ^[1]A1b. Rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily reduced the primary composite outcome (acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke, or cardiovascular death) from 19.9% to 17.3% at 3 years (HR 0.85; 95% CI 0.76-0.96; p=0.009; NNT ≈ 39). TIMI major bleeding did not differ significantly (2.65% vs 1.87%; HR 1.43; p=0.07), but ISTH major bleeding was higher (5.94% vs 4.06%; HR 1.42; p=0.007). The benefit was consistent across subgroups, including fragile patients (age >75, weight ≤50 kg, eGFR <50 mL/min/1.73 m²) ^[72]A1b and those with prior revascularization ^[19]B2b. Net clinical benefit analyses confirmed a favorable risk-benefit profile ^[20]B2b.

EUCLID (2016) compared ticagrelor 90 mg twice daily with clopidogrel 75 mg daily as monotherapy in 13,885 patients with symptomatic peripheral artery disease ^[11]A1b. The primary efficacy endpoint (cardiovascular death, myocardial infarction, or ischemic stroke) occurred in 10.8% vs 10.6% (HR 1.02; 95% CI 0.92-1.13; p=0.65). Acute limb ischemia occurred in 1.7% of each group. Ticagrelor was not superior to clopidogrel, and the two agents are considered equivalent for PAD ^[11]A1b.

The ASPIRIN trial (2025) addressed the role of adding aspirin to oral anticoagulation in patients with chronic coronary syndrome at high atherothrombotic risk ^[10]A1b. The trial was stopped early because of excess mortality in the aspirin group: all-cause death occurred in 13.4% vs 8.4% (adjusted HR 1.72; 95% CI 1.14-2.58; p=0.01; NNH ≈ 20 for death). Major bleeding was also increased (10.2% vs 3.4%; HR 3.35; 95% CI 1.87-6.00; p<0.001; NNH ≈ 15). This trial has shifted practice away from routine triple therapy.

Emerging Approaches

Fesomersen , a factor XI inhibitor, is being investigated in patients with kidney failure on hemodialysis ^[83]A1b. In a phase II trial, fesomersen produced dose-dependent reductions in FXI levels (up to 86% with 120 mg monthly) with similar major bleeding rates to placebo (4.0% vs 4.0% for pooled fesomersen) and reductions in hemodialysis circuit clotting (p=0.002). Phase III trials are needed to determine whether this agent can reduce ALI and other thrombotic events without increasing bleeding.

These trials have refined the evidence base, but the prognosis after ALI remains guarded, 30-day mortality of 10-15% and amputation rates of 10-30% depending on severity, which will be discussed in the next section.

Pearl: The ASPIRIN trial showed that adding aspirin to oral anticoagulation increases mortality and major bleeding, discouraging routine triple therapy ^[10]A1b.

Although revascularization techniques have evolved substantially, the prognosis of acute limb ischemia (ALI) remains guarded. Contemporary series report 30-day mortality rates of 9- and major amputation rates of up to 25%, with the highest risk in patients who present with irreversible ischemia or severe comorbidities ^[84]C4. The natural history of untreated ALI is uniformly poor: without timely restoration of blood flow, ischemic muscle necrosis progresses within 6-12 hours, leading to inevitable limb loss and, frequently, death from sepsis, renal failure, or reperfusion injury.

Mortality and Amputation Rates

In a prospective cohort of 42 patients with ALI, 30-day outcomes included a major amputation rate of (6 of 42) and a mortality rate of (4 of 42) ^[84]C4. A larger contemporary series of 220 patients (2007-2015) reported 30-day limb salvage of 95% and survival of 82.3%; by 90 days, limb salvage remained 95% but survival declined to 74.1% ^[14]C4. Patients with acute thrombosis fared worse than those with embolism, with independent risk factors for amputation including diabetes, severe neuro-ischemic impairment, acute arterial thrombosis, and treatment delay >1 day after vascular consultation ^[14]C4.

In the subset of patients with popliteal artery aneurysm (PAA) requiring urgent repair, 5-year limb salvage was 83±6% and 5-year survival was 71±7% ^[13]B3b. Ruptured PAAs carried a particularly grim prognosis: 5-year survival dropped to 48±2% compared with 79±7% for those presenting with ALI without rupture ^[13]B3b. The number of patent tibial arteries (pTA) was the strongest independent predictor of both limb salvage (HR 0.14, 95% CI 0.03-0.6) and survival (HR 0.15, 95% CI 0.03-0.8) ^[13]B3b.

Factors Influencing Prognosis

Several clinical and laboratory variables stratify risk of adverse outcomes:

• Treatment delay: Any delay >1 day after vascular consultation independently increases amputation risk ^[14]C4.
• ALI severity: Rutherford class IIb (threatened) and III (irreversible) carry higher amputation and mortality rates; severe neuro-ischemic impairment is an independent predictor ^[14]C4.
• Comorbidities: Diabetes, heart disease, and dyslipidemia are independently associated with mortality ^{[14]C4[28]B3b}. Anemia (HR 1.81, p=0.014) and ALI severity (HR 1.73, p=0.032) independently predict lower survival in nonagenarians ^[62]C4.
• Biomarkers: An elevated neutrophil-to-lymphocyte ratio (NLR) is a strong predictor of short-term outcomes: high NLR confers a 9-fold increased risk of 30-day all-cause mortality and a 7.5-fold increased risk of 30-day amputation ^[60]B2a.

Natural History of Untreated ALI

Without intervention, the ischemic limb progresses through a predictable sequence: sensory loss (within 6 hours), motor paralysis (within 12 hours), and finally irreversible tissue necrosis. The window for salvage is narrow, and patient delay, the time from symptom onset to first medical contact, is the largest contributor to treatment delay, with a median of 24 hours (range 0-1200 hours) in one series ^[84]C4. Once irreversible ischemia is established (Rutherford III), amputation is inevitable, and attempted revascularization may precipitate life-threatening reperfusion injury.

Long-Term Outcomes and Dual-Pathology Burden

Survivors of an ALI episode remain at high risk for both cardiovascular events and recurrent limb ischemia. In the VOYAGER-PAD trial, patients with prior lower extremity revascularization had a 1.58-fold higher rate of major adverse limb events (MALE) at 3 years compared with those without prior revascularization (12.9% vs 8.0%) ^[19]B2b. Low-dose rivaroxaban (2.5 mg twice daily) plus aspirin reduced this risk, with a numerically greater relative benefit in those with prior revascularization (HR 0.73) ^[19]B2b. Importantly, the net clinical benefit of rivaroxaban was favorable, with ischemic risk reduction outweighing bleeding risk ^[20]B2b.

Nonagenarians treated for ALI had a 1-year survival of only 48%, and even those surviving the acute episode had a significantly lower 1-year survival compared with an age-matched general population ^[62]C4. This underscores the need for aggressive secondary prevention, including antiplatelet therapy, statins , and risk factor modification, in all patients who survive an ALI episode.

Pearl: The strongest modifiable predictor of outcome in ALI is time to revascularization; every hour of delay beyond 24 hours from symptom onset increases the risk of amputation, and the patient's own delay in seeking care is the rate-limiting step ^[84]C4.

The prognosis data above underscore that age, comorbidity burden, and physiologic reserve profoundly alter outcomes. Three populations, children, the very elderly, and immunocompromised patients, require explicit deviation from the standard diagnostic and therapeutic pathway because their presentation, risk profile, and treatment tolerance differ substantially.

Pediatrics

Pediatric acute limb ischemia (PALI) is overwhelmingly iatrogenic: arterial cannulation accounts for 89.9% of cases in a pooled analysis of 2484 children (mean age 2.14 years; 66.3% male) ^[16]C4. The common femoral artery is the most frequently affected site (49.8%) ^[16]C4.

• Diagnosis: Ultrasound is the first-line imaging modality; it avoids ionizing radiation and can be performed at the bedside ^[16]C4.
• Treatment: Conservative management (systemic heparinization, limb elevation, close observation) is first-line in 87% of cases and is successful without surgical intervention in 65% of reported series ^[16]C4. Surgery is reserved for failed conservative therapy.
• Outcomes: Amputation rate is low at 2.4%; mortality directly attributable to PALI is 0.01% ^[16]C4.
• Key modification: Avoid routine thrombolysis unless limb threat is imminent; the developing vasculature and higher bleeding risk favor a conservative-first approach.

Pregnancy

Pregnancy is a hypercoagulable state that increases the risk of thromboembolism, though ALI in pregnancy is rare. No randomized trials guide management; evidence is limited to case reports.

• Diagnosis: Duplex ultrasound is preferred to avoid fetal radiation exposure. If cross-sectional imaging is necessary, MRI without gadolinium is safer than CT angiography.
• Treatment modifications: Unfractionated heparin is the anticoagulant of choice because it does not cross the placenta. Thrombolysis is relatively contraindicated due to bleeding risk (uterine, placental). Surgical embolectomy under locoregional anesthesia is preferred when feasible.
• Delivery planning: If revascularization is required, obstetric and neonatal teams should be involved preoperatively. Postpartum anticoagulation must account for breastfeeding safety (heparin and warfarin are compatible; direct oral anticoagulants lack sufficient data).

Elderly (Nonagenarians)

Nonagenarians represent a growing ALI cohort. In a consecutive series of 102 patients (mean age 92.4 years; 78.4% women), 81.4% of ALI episodes were embolic ^[62]C4.

• Presentation: Often delayed due to cognitive impairment or atypical symptoms. Anemia (HR 1.81, p=0.014) and ALI severity (HR 1.73, p=0.032) independently predict lower survival ^[62]C4.
• Treatment: Despite frailty, 85.3% of nonagenarians underwent revascularization (67.6% embolectomy). One-year limb salvage was 96%, but 1-year survival was only 48% ^[62]C4. Palliative care was chosen in 14.7% (irreversible ischemia, advanced dementia, malignancy) and none survived beyond 10 days ^[62]C4.
• Key modification: Do not automatically withhold revascularization based on age alone. Cognitive and functional status did not predict survival in this series ^[62]C4. However, comorbid anemia and severe ischemia should prompt realistic shared decision-making.
• Perioperative risk: Open surgery carries higher in-hospital mortality (aOR 1.25) and nonhome discharge (aOR 1.82) compared with endovascular approaches ^[63]B3b. In frail elderly, an endovascular-first strategy may reduce perioperative morbidity.

Immunocompromised

Immunocompromised patients (solid organ transplant, chronic immunosuppression, HIV, active malignancy) face higher risks of infectious complications after revascularization. Open surgery is associated with greater odds of infectious complications (aOR 1.19) compared with endovascular therapy ^[63]B3b.

• Diagnosis: Maintain a low threshold for imaging; atypical presentations (e.g., fungal emboli) may mimic ALI.
• Treatment modifications: Perioperative antibiotic prophylaxis should be broadened to cover skin flora and opportunistic pathogens. Graft infection risk is elevated; if a prosthetic graft is used, consider antibiotic-impregnated beads or autologous conduit ^[26]C4.
• Outcomes: Wound sterilization can be achieved in 94.1% with antibiotic beads and muscle flap closure, with limb salvage of 86.5% at mean 26 months ^[26]C4. Reinfection rate is 12.5% in graft-preservation cases ^[26]C4.

Pearl: In pediatric ALI, conservative management succeeds in two-thirds of cases; in nonagenarians, revascularization yields excellent limb salvage despite limited long-term survival, do not deny surgery based on age alone, but do involve palliative care when ischemia is irreversible or comorbidities are overwhelming.

Beyond the acute revascularization and perinatal considerations discussed in the preceding section, the long-term care of the ALI patient centers on three pillars: primary prevention of atherothrombotic events, secondary prevention of recurrence, and structured surveillance for underlying pathology.

Primary Prevention of Atherothrombotic Events

Primary prevention of ALI mirrors that of peripheral artery disease (PAD) generally. For patients aged ≥50 years with asymptomatic PAD or asymptomatic carotid stenosis, aspirin 75-100 mg/d is suggested over no therapy (Grade 2B) for the primary prevention of cardiovascular events ^[85]A1c. Aggressive risk-factor modification, smoking cessation, statin therapy, blood pressure control, is paramount. In a cohort of young PAD patients (age <50 years), 93% were smokers; recurrence occurred in 47.1% of patients, all of whom were active smokers ^[89]C4. Acute limb ischemia at diagnosis carried an odds ratio of 5.95 for major amputation ^[89]C4.

Secondary Prevention and Medical Therapy

After an ALI episode, long-term antiplatelet therapy is mandatory. The ACCP 9th edition guidelines recommend aspirin 75-100 mg/d or clopidogrel 75 mg/d for secondary prevention of cardiovascular events in symptomatic PAD, including prior ALI (Grade 1A) ^[85]A1c. For patients with a prior myocardial infarction and concomitant PAD, the PEGASUS- TIMI 54 trial demonstrated that ticagrelor 60 mg twice daily added to low-dose aspirin reduces major adverse cardiovascular events (MACE) by an absolute 4.1% (NNT = 25) and major adverse limb events (MALE) by 35% (HR 0.65, 95% CI 0.44-0.95) ^[86]A1b. The absolute excess of TIMI major bleeding was 0.12% (NNH = 834) ^[86]A1b. In cryptogenic ALI, where no precipitant is identified, retrospective data show a recurrence rate of 25% over a median follow-up of 23.3 months, and none of the recurrent patients were therapeutically anticoagulated, suggesting indefinite anticoagulation may be warranted ^[88]B3b.

Screening for Underlying Etiology

In patients presenting with ALI of unclear etiology, screening for an underlying cancer is warranted. A meta-analysis of 2899 patients found that ALI can be the first manifestation of malignancy; 1-year mortality after ALI in patients with established cancer was 50.6% vs 29.9% in those diagnosed before cancer, and the overall 1-year mortality was 52.3% (95% CI 37.7%-) ^[87]A1a. Vascular imaging (CTA or duplex ultrasound) should also be performed to exclude aneurysmal sources (popliteal, sciatic) or persistent sciatic artery, which presents as ALI in 33-75% of cases ^{[90]C4[91]B2a[92]C4}. Radiation-induced arteriopathy should be considered in patients with prior pelvic radiotherapy, with a median symptom latency of 12 years ^[70]C4.

Post-Revascularization Surveillance

After revascularization, a surveillance plan is essential ^[93]D5. For graft infections, antibiotic polymethylmethacrylate beads achieve wound sterilization in 94.1% of cases, but reinfection occurs in 12.5% ^[26]C4. For persistent sciatic artery aneurysms treated with covered stents, long-term surveillance with CTA or duplex ultrasound is crucial, as mid-term follow-up (mean 22 months) shows no symptom recurrence ^{[91]B2a[92]C4}. Overall, 2-year primary patency after open repair of peripheral aneurysms is 81.25% ^[90]C4.

Patient Education

Patients must be counseled on smoking cessation, medication adherence, and recognition of recurrent ischemia symptoms (pain, pallor, pulselessness). Structured exercise rehabilitation, though not directly studied in ALI, is recommended for claudication to improve collateral flow ^[93]D5.

Pearl: After an episode of cryptogenic ALI, a 25% recurrence rate supports strong consideration of indefinite anticoagulation ^[88]B3b; in patients with prior MI and PAD, ticagrelor 60 mg twice daily on aspirin yields NNT of 25 for MACE prevention ^[86]A1b.